NL-OMON36999已完成不适用
Enhancing anti-melanoma activity of T-cells - MIO, Melanoma Immunotherapy Optimization
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •patients with primary and/or metastasized melanoma who need to undergo a surgical procedure
排除标准
- •no exclusion criteria;
研究者
相似试验
已完成
不适用
Integrated analyses of melanoma-T cell interactions; relevance for immunotherapy100276651004090010035023skin cancerNL-OMON29970KI-AV40
进行中（未招募）
1 期
Treatment of skin cancer using a different approach than surgery using an electroporation device that makes the tumour absorb more drug while leaving the healthy tissue alone combined with an immune modulator that enhances the anti-tumour immune response.Advanced Melanoma CancerEUCTR2014-004420-22-IEniversity College Cork10
终止
2 期
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV MelanomaMelanoma (Skin)NCT00006113University of Southern California25
已完成
1 期
T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple MyelomaMyeloma-MultipleMyeloma, Plasma-CellNCT03958656National Cancer Institute (NCI)13
已完成
2 期
Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic MelanomaMalignant MelanomaMelanoma, ExperimentalExperimental MelanomasMelanomaNCT00513604National Cancer Institute (NCI)158